These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1760523)

  • 21. Hyperthyroidism in Patients with Graves' Ophthalmopathy, and Thyroidal, Skeletal and Eye Muscle Specific Type 2 Deiodinase Enzyme Activities.
    Molnár I; Szentmiklósi JA; Somogyiné-Vári É
    Exp Clin Endocrinol Diabetes; 2017 Sep; 125(8):514-521. PubMed ID: 28750432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease.
    Yamada T; Sato A; Komiya I; Nishimori T; Ito Y; Terao A; Eto S; Tanaka Y
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2775-8. PubMed ID: 10946880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy.
    Gerding MN; van der Meer JW; Broenink M; Bakker O; Wiersinga WM; Prummel MF
    Clin Endocrinol (Oxf); 2000 Mar; 52(3):267-71. PubMed ID: 10718823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in thyroid volume during antithyroid drug therapy for Graves' disease and its relationship to TSH receptor antibodies, TSH and thyroglobulin.
    Yamaguchi Y; Inukai T; Iwashita A; Nishino M; Yamaguchi T; Shohda Y; Shimomura Y; Ohshima K; Kobayashi S; Kobayashi I
    Acta Endocrinol (Copenh); 1990 Oct; 123(4):411-5. PubMed ID: 1978459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methimazole has no dose-related effect on the serum concentrations of soluble class I major histocompatibility complex antigens, soluble interleukin-2 receptor, and beta 2-microglobulin in patients with Graves' disease.
    Escobar-Morreale HF; Serrano-Gotarredona J; Villar LM; García-Robles R; González-Porqué P; Sancho JM; Varela C
    Thyroid; 1996 Feb; 6(1):29-36. PubMed ID: 8777381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of long-term follow-up and methimazole therapy outcomes of pediatric Graves' disease: a single-center experience.
    Bayramoğlu E; Elmaogulları S; Sagsak E; Aycan Z
    J Pediatr Endocrinol Metab; 2019 Apr; 32(4):341-346. PubMed ID: 30862763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Analysis of costimulatory molecules (CD28-CTLA-4/B7) expression on chosen mononuclear cells in adolescents with Graves' disease during methimazole therapy].
    Bossowski A; Stasiak-Barmuta A; Urban M; Rinderle C
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2004; 10(2):93-101. PubMed ID: 15504312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma selectin levels in patients with Graves' disease.
    Hara H; Sugita E; Sato R; Ban Y
    Endocr J; 1996 Dec; 43(6):709-13. PubMed ID: 9075611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Remission and recurrence of hyperthyroid Graves' disease during and after methimazole treatment when assessed by IgE and interleukin 13.
    Komiya I; Yamada T; Sato A; Kouki T; Nishimori T; Takasu N
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3540-4. PubMed ID: 11502776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thyroid vascularization by color doppler ultrasonography in Graves' disease. Changes related to different phases and to the long-term outcome of the disease.
    Baldini M; Castagnone D; Rivolta R; Meroni L; Pappalettera M; Cantalamessa L
    Thyroid; 1997 Dec; 7(6):823-8. PubMed ID: 9459623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence and significance of antibodies reactive with eye muscle membrane antigens in sera from patients with Graves' ophthalmopathy and other thyroid and nonthyroid diseases.
    Wu YJ; Clarke EM; Shepherd P
    Thyroid; 1998 Feb; 8(2):167-74. PubMed ID: 9510126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Soluble intercellular adhesion molecule-1 (sICAM-1) concentrations in Graves' disease patients followed up for development of ophthalmopathy.
    De Bellis A; Di Martino S; Fiordelisi F; Muccitelli VI; Sinisi AA; Abbate GF; Gargano D; Bellastella A; Bizzarro A
    J Clin Endocrinol Metab; 1998 Apr; 83(4):1222-5. PubMed ID: 9543145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
    Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
    Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medical therapy of Graves' disease: effect on remission rates of methimazole alone and in combination with triiodothyronine.
    Raber W; Kmen E; Waldhäusl W; Vierhapper H
    Eur J Endocrinol; 2000 Feb; 142(2):117-24. PubMed ID: 10664518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study.
    Cappelli C; Gandossi E; Castellano M; Pizzocaro C; Agosti B; Delbarba A; Pirola I; De Martino E; Rosei EA
    Endocr J; 2007 Dec; 54(5):713-20. PubMed ID: 17675761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.
    Murakami M; Koizumi Y; Aizawa T; Yamada T; Takahashi Y; Watanabe T; Kamoi K
    J Clin Endocrinol Metab; 1988 Jan; 66(1):103-8. PubMed ID: 3121661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical utility of thyrotropin-receptor antibody assays: comparison of radioreceptor and bioassay methods.
    Morris JC; Hay ID; Nelson RE; Jiang NS
    Mayo Clin Proc; 1988 Jul; 63(7):707-17. PubMed ID: 2898572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.
    Carella C; Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Nersita R; Iorio S; Amato G; Braverman LE; Roti E
    Thyroid; 2006 Mar; 16(3):295-302. PubMed ID: 16571093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum antibodies to collagen XIII: a further good marker of active Graves' ophthalmopathy.
    De Bellis A; Sansone D; Coronella C; Conte M; Iorio S; Perrino S; Battaglia M; Bellastella G; Wall JR; Bellastella A; Bizzarro A
    Clin Endocrinol (Oxf); 2005 Jan; 62(1):24-9. PubMed ID: 15638866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A study of untreated Graves' patients with undetectable TSH binding inhibitor immunoglobulins and the effect of anti-thyroid drugs.
    Kawai K; Tamai H; Matsubayashi S; Mukuta T; Morita T; Kubo C; Kuma K
    Clin Endocrinol (Oxf); 1995 Nov; 43(5):551-6. PubMed ID: 8548939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.